Microchip Biotechnologies, Inc. Selected for Participation in the US Army Commercialization Pilot Program

DUBLIN, Calif., Jan. 2 Microchip Biotechnologies, Inc.(MBI) has been selected for participation in the inaugural US ArmyCommercialization Pilot Program. The Commercialization Pilot Program is a newprogram to identify SBIR firms that have Phase II projects with hightransition potential to commercial products that meet high priority Armyrequirements. MBI was identified as one of 25 firms selected out of 529eligible firms and 416 applicants (http://www.armysbir.com/sbir/cpp_fy08.htm).MBI has been developing a biothreat detection system under Army SBIR funding."The acceptance of MBI by the Army to participate in the CPP is a furthervalidation of our commitment to develop and commercialize microfluidictechnologies for the protection of the combat troops and civilianpopulations," said Dr. Stevan Jovanovich, President and CEO of MBI.

About Microchip Biotechnologies, Inc.

Microchip Biotechnologies, Inc. is a privately-held company located inDublin, California that is developing the Apollo next-generation fluidicsplatform for Life Sciences, Applied Sciences, and Diagnostics markets. TheApollo platform integrates advanced microfluidic sample preparation andanalytical capabilities to produce sample-to-answer performance for DNAsequencing, biodefense, forensics, and molecular diagnostics applications.The Apollo platform incorporates MBI's proprietary BeadStorm(TM) bead-basedsample preparation devices and "Microscale On-Chip" (MOV(TM)) valves, pumps,and routers on microchips. More details can be found on the Company'swebsite: http://www.microchipbiotech.com.

SOURCE Microchip Biotechnologies, Inc.

Latest Press Release on General News

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers usi...

Philips Shareholders Approve all Proposals at the AGM 2024

May 7, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that its shareholders approved all proposals at the Annual General Meeting of Shar...

Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division

VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterin...

Nicklaus Children's Health System, Philips to Provide Innovative Patient and Staff Experience, Helping to Enhance Outcomes for the Smallest of Patients

April 30, 2024 Philips AI-enabled diagnostic and experiential technologies help put patients at ease while empowering staff with faster, high-quality scans and increased diagnostic c...

Cinesteam® Is a Deodorizing Support Tool for Palliative Care

Palliative Care Is a Comprehensive Approach to Long-Term Patient Care. Caregivers Can Use Cinesteam®'s Secondary Dressings to Improve Quality of Life in Palliative Care Settings. FOR...